Rheumatoid Arthritis: What to Do When Methotrexate Does Not Reach Disease Targets and No Poor Prognostic Factors Are Present
Clinical scenario
This protocol applies to patients with rheumatoid arthritis who have received methotrexate as their first conventional synthetic DMARD strategy but have not achieved the required disease-activity targets — and who do not carry features associated with a poor prognosis.
Specifically: no contraindication to methotrexate and no early intolerance; no high-level RF or ACPA positivity; no persistently moderate or high disease activity on prior csDMARD therapy; no high swollen joint count; no elevated acute phase reactants; no early erosions; and no failure of two or more csDMARDs. In this setting, escalation within the conventional synthetic DMARD class is recommended before considering biologic agents.
Previous treatment — failure condition
First-line therapy that did not meet its targets
Methotrexate (up to 25 mg once weekly, orally or parenterally) with folic acid supplementation, combined with short-term glucocorticoids as bridging therapy. The goals that were not reached: at least 50% improvement in disease activity by 3 months, and sustained remission or low disease activity by 6 months.
Treatment approach (partial overview)
The next step involves switching to or adding a second conventional synthetic DMARD, combined with a short course of glucocorticoids — full regimen details, drug selection, sequencing, and monitoring guidance are in the complete protocol.
Clinical targets for this protocol
- At least 50% improvement in disease activity within 3 months
- Sustained remission or low disease activity by 6 months
References
DOI: 10.1136/ard-2022-223356
- MTX should be part of the first treatment strategy.
- If the treatment target is not achieved with the first csDMARD strategy, in the absence of poor prognostic factors, other csDMARDs should be considered.
- Short-term glucocorticoids should be considered when initiating or changing csDMARDs, in different dose regimens and routes of administration, but should be tapered and discontinued as rapidly as clinically feasible.
- Treatment should be aimed at reaching a target of sustained remission or low disease activity in every patient.
- Monitoring should be frequent in active disease (every 1–3 months); if there is no improvement by at most 3 months after the start of treatment or the target has not been reached by 6 months, therapy should be adjusted.
View source ↗